Główny Inspektorat Farmaceutyczny

CERTIFICATE NUMBER: IWPS.405.34.2019.KKW.1 WTC/0589 01 01/60

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with:

The competent authority of Poland confirms the following:

The manufacturer: Macleods Pharmaceuticals Limited

Site address: Village ThedaPost Office LodhimajraTehsil Baddi, District Solan, Himachal Pradesh, 174101, India

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2019-01-18, it is considered that it complies with:

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 58058 Issuance Date 2019-04-16 Signatory: Confidential

¹The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

 $^{^2}$ Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³These requirements fulfil the GMP recommendations of WHO.

Part 2

1.2	Non-sterile products
	1.2.1 Non-sterile products (processing operations for the following dosage forms)
	1.2.1.1 Capsules, hard shell
	1.2.1.6 Liquids for internal use
	1.2.1.13 Tablets
1 5	Paraba situa
1.5	Packaging
	1.5.2 Secondary packaging
1.6	Quality control testing
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical

Clarifying remarks (for public users)

Block N2 approved only.

2019-04-16

Name and signature of the authorised person of the Competent Authority of Poland

Confidential
Chief Pharmaceutical Inspectorate
Tel:Confidential

Fax: Confidential